Бевацизумаб (Авастин) – новые возможности в лечении злокачественных опухолей


И.П. Ганьшина, Н.Н. Семенов, М.Р. Личиницер

Бевацизумаб (Авастин) - новые возможности в лечении злокачественных опухолей
Рассматриваются перспективы использования в онкологии бевацизумаба (Авастина) - химерных человеческих рекомбинантных антител против фактора роста эндотелия сосудов (VEGF) - важнейшего регулятора физиологического и патологического ангиогенеза. Показано, что экспрессия VEGF в первичной опухоли коррелирует с высоким риском рецидива заболевания и плохим прогнозом при различных новообразованиях. Приводятся обнадеживающие результаты применения бевацизумаба при раке молочной железы, колоректальном раке, немелкоклеточном раке легкого в качестве монотерапии и в комбинации с различными химиотерапевтическими схемами. Полученные данные свидетельствуют, что использование бевацизумаба позволяет увеличить общую выживаемость и время до прогрессирования различных опухолей. Обсуждаются возможности применения бевацизумаба по новым показаниям.

Литература






  1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353–64.
  2. Ferrara N, Gerber HP. The biology of VEGF and its receptors. Nat Med 2003;9:669–76.
  3. Pegran MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER/2neu protein and vascular endothelial factor. Semin Oncol 2002;29(suppl. 11):29–37.
  4. Gordon MS, Margolin K, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19: 843–50.
  5. Margolin K, Gordon MS, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacological and long-term safety data. J Clin Oncol 2001;19:851–56.
  6. MCCulloch, et al. Association betwen tumor angiogenesis and tumor cell shedding into effluent venosus blood during breast cancer surgery. Lancet 1995;346:1334–35.
  7. Ellis LM, Walker RA. Is determination of angiogenic activity in human tumors clinicaly useful? Eur J Cancer 1998;34:609–18.
  8. Presta LG Chen H, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disoders. Cancer Res 1997;57:4593–99.
  9. Harmey JH, Bouchier-Hayes D. Vascular endothelial growth factor, a survial factor for tumour cells:implications for anti-angiogenic therapy. Bioessays 2002;24:280–83.
  10. Hope S. Rugo. Bevacizumab in the treatment of breast cancer: rationale and current data. The Oncologist 2004;9(suppl. 1):43–49.
  11. Miller KD, Rugo HS, et al. Phase III trial of capecitabine plus bevacizumab versus capecitabine alone in women with metastatic breast cancer previously treated with anthracycline and taxane. Breast Cancer Res Treat 2002;76(suppl. 1):S37.
  12. Lee JC, Chow NH, Wang ST, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748–53.
  13. Frank RE, Saclarides TJ, Leurgans S, et al. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 1995;222:695–99.
  14. Choi HJ, Hyun MS, Jung GJ et al. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology 1998;55: 575–81.
  15. Kabbinavar F, et al Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60–65.
  16. Hurwitz H, et al. Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin for the treatment of metastatic colorectal cancer: results of a randomized phase III trial. N Engl J Med 2004.
  17. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–98.
  18. Giatromanolaki A. Prognostic role of angiogenesis in non-small cell lung cancer. Anticancer Res 2001;21:4373–82.
  19. Mininberg ED, Herbst RS, Henderson T, et al. Phase I/II study of recombinant humanized monoclonal anti-VEGF antibody bevacizumab and EGFR-TK inhibitor erlotinib HCl in patients with recurrent non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003;22:627.



Бионика Медиа